BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $38 from $45 and keeps a Buy rating on the shares. The firm ...

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

Management projected strong growth for 2025, driven by expanded reimbursement in key European markets such as Spain and Italy and the expected completion of the post-approval efficacy study (PAES).

It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

Julian Harrison, an analyst from BTIG, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...

Myasthenia gravis (MG) is a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. For most people with MG, the disease is characterized by the presence of antibodies against ...

1 Department of Neurology, Affiliated Hospital of Yangzhou University, Yangzhou, China 2 Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China Myasthenia gravis (MG) is an ...

NEW YORK – Cartesian Therapeutics expects to launch a randomized, controlled Phase III trial, dubbed AURORA, to evaluate its investigational cell therapy for myasthenia gravis in the first half of the ...

Cemdisiran is under clinical development by Alnylam Pharmaceuticals and currently in Phase III for Myasthenia Gravis. According to GlobalData, Phase III drugs for Myasthenia Gravis have a 70% phase ...

The Ministry of Food and Drug Safety announced on the 20th that it has approved the severe myasthenia gravis treatment "Vyvgart" (active ingredient efgartigimod alpha) from Belgian pharmaceutical ...